Kasvu Therapeutics

Latest updates, news releases and upcoming events.

Kasvu Therapeutics advances neuroplasticity treatments for mental health with €30M Series A funding. Focused on developing selective TrkB potentiators for depression and neuropsychiatric disorders.

The company’s multidisciplinary international team includes original inventors and qualified drug developers from the global pharmaceutical industry who partner with drug discovery CROs.

The company aims to deliver solutions for a medical challenge.

Kasvu develops small-molecule neuroplastogens for diseases involving altered neuronal connectivity. The compounds are described as potent, rapid-acting, long-lasting, and non-hallucinogenic.

Kasvu develops small-molecule neuroplastogens for diseases involving altered neuronal connectivity. The compounds are described as potent, rapid-acting, long-lasting, and non-hallucinogenic.

Highly Capitalized covers Kasvu’s €30 million financing and the ongoing development of its investigational TrkB program.

Sep 2026 · Highly CapitalizedNews article

Kasvu Therapeutics raises a €30 million Series A financing backed by Hadean Ventures and Tesi. Roschier reports advising Hadean Ventures and Tesi in the financing.

Sep 2026 · RoschierNews article

Kasvu raises $34 million in Series A financing to develop an alternative treatment for depression. Its CEO discusses the company’s investigational program targeting TrkB.

Sep 2026 · BioXconomyNews article

Kasvu Therapeutics announces a €30 million Series A led by Hadean Ventures to support preclinical development of its TrkB-modulating candidate KTX-0141.

Sep 2026 · Kasvu TherapeuticsNews article